Invasive Aspergillosis: Resistance to Antifungal Drugs

Mycopathologia

Volumn 174, Issue 2, 2012, Pages 131-141

  Hadrich, Inès ^a   Makni, Fattouma ^a   Neji, Sourour ^a   Abbes, Salma ^a   Cheikhrouhou, Fatma ^a   Trabelsi, Houaida ^a   Sellami, Hayet ^a   Ayadi, Ali ^a  

^a UNIVERSITY OF SFAX   (Tunisia)

Author keywords

Antifungal resistance; Aspergillus species; Invasive aspergillosis; Mechanisms

Indexed keywords

ANTIFUNGAL AGENT;

ANTIFUNGAL RESISTANCE; ASPERGILLUS; DRUG EFFECT; HUMAN; ISOLATION AND PURIFICATION; LUNG ASPERGILLOSIS; MICROBIOLOGY; REVIEW;

ANTIFUNGAL AGENTS; ASPERGILLUS; DRUG RESISTANCE, FUNGAL; HUMANS; INVASIVE PULMONARY ASPERGILLOSIS;

ASPERGILLUS;

EID: 84864278238     PISSN: 0301486X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11046-012-9526-y     Document Type: Review

References (95)

1. Kontoyiannis DP, Bodey GP. Invasive aspergillosis in 2002: an update. Eur J Clin Microbiol Infect Dis. 2002; 21: 161-72.
2. Herbrecht R, Denning DW, Patterson TF, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med. 2002; 347: 408-15.
3. Odds FC, Brown AJ, Gow NA. Antifungal agents: mechanisms of action. Trends Microbiol. 2003; 11: 272-9.
4. Groll AH, Silling G, Young C, et al. Randomized comparison of safety and pharmacokinetics of caspofungin, liposomal amphotericin B, and the combination of both in allogeneic hematopoietic stem cell recipients. Antimicrob Agents Chemother. 2010; 54: 4143-9.
5. Marr KA, Carter RA, Crippa F, Wald A, Corey L. Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin Infect Dis. 2002; 34: 909-17.
6. Sutton DA, Sanche SE, Revankar SG, Fothergill AW, Rinaldi MG. In vitro amphotericin B resistance in clinical isolates of Aspergillus terreus, with a head-to-head comparison to voriconazole. J Clin Microbiol. 1999; 37: 2343-5.
7. Lass-Florl C, Rief A, Leitner S, Speth C, Wurzner R, Dierich MP. In vitro activities of amphotericin B and voriconazole against aleurioconidia from Aspergillus terreus. Antimicrob Agents Chemother. 2005; 49: 2539-40.
8. Alcazar-Fuoli L, Mellado E, Alastruey-Izquierdo A, Cuenca-Estrella M, Rodriguez-Tudela JL. Aspergillus section Fumigati: antifungal susceptibility patterns and sequence-based identification. Antimicrob Agents Chemother. 2008; 52: 1244-51.
9. Pfaller MA, Messer SA, Boyken L, et al. In vitro survey of triazole cross-resistance among more than 700 clinical isolates of Aspergillus species. J Clin Microbiol. 2008; 46: 2568-72.
10. Guinea J, Bouza E. Isavuconazole: a new and promising antifungal triazole for the treatment of invasive fungal infections. Future Microbiol. 2008; 3: 603-15.
11. Guinea J, Pelaez T, Recio S, Torres-Narbona M, Bouza E. In vitro antifungal activities of isavuconazole (BAL4815), voriconazole, and fluconazole against 1, 007 isolates of zygomycete, Candida, Aspergillus, Fusarium, and Scedosporium species. Antimicrob Agents Chemother. 2008; 52: 1396-400.
12. Howard SJ, Cerar D, Anderson MJ, et al. Frequency and evolution of Azole resistance in Aspergillus fumigatus associated with treatment failure. Emerg Infect Dis. 2009; 15: 1068-76.
13. Snelders E, Huis In't Veld RA, Rijs AJ, Kema GH, Melchers WJ, Verweij PE. Possible environmental origin of resistance of Aspergillus fumigatus to medical triazoles. Appl Environ Microbiol. 2009; 75: 4053-7.
14. Verweij PE, Snelders E, Kema GH, Mellado E, Melchers WJ. Azole resistance in Aspergillus fumigatus: a side-effect of environmental fungicide use? Lancet Infect Dis. 2009; 9: 789-95.
15. Arendrup MC, Garcia-Effron G, Buzina W, et al. Breakthrough Aspergillus fumigatus and Candida albicans double infection during caspofungin treatment: laboratory characteristics and implication for susceptibility testing. Antimicrob Agents Chemother. 2009; 53: 1185-93.
16. Andes D. Clinical utility of antifungal pharmacokinetics and pharmacodynamics. Curr Opin Infect Dis. 2004; 17: 533-40.
17. Pascual A, Calandra T, Bolay S, Buclin T, Bille J, Marchetti O. Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes. Clin Infect Dis. 2008; 46: 201-11.
18. Segal BH, Herbrecht R, Stevens DA, et al. Defining responses to therapy and study outcomes in clinical trials of invasive fungal diseases: Mycoses Study Group and European Organization for Research and Treatment of Cancer consensus criteria. Clin Infect Dis. 2008; 47: 674-83.
19. Boutboul F, Alberti C, Leblanc T, et al. Invasive aspergillosis in allogeneic stem cell transplant recipients: increasing antigenemia is associated with progressive disease. Clin Infect Dis. 2002; 34: 939-43.
20. Maertens J, Vrebos M, Boogaerts M. Assessing risk factors for systemic fungal infections. Eur J Cancer Care. 2001; 10: 56-62.
21. Khayyata S, Soubani AO, Bonnett M, Nassar H, Abidi MH, Al-Abbadi MA. The major autopsy findings in adult patients after hematopoietic stem cell transplantation. Ann Transpl. 2007; 12: 11-8.
22. Pfaller MA, Boyken L, Hollis RJ, et al. In vitro susceptibility of clinical isolates of Aspergillus spp. to anidulafungin, caspofungin, and micafungin: a head-to-head comparison using the CLSI M38-A2 broth microdilution method. J Clin Microbiol. 2009; 47: 3323-5.
23. Espinel-Ingroff A, Diekema DJ, Fothergill A, et al. Wild-type MIC distributions and epidemiological cutoff values for the triazoles and six Aspergillus spp. for the CLSI broth microdilution method (M38-A2 document). J Clin Microbiol. 2010; 48: 3251-7.
24. Araujo R, Espinel-Ingroff A. Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole. Antimicrob Agents Chemother. 2009; 53: 4921-3.
25. Buchta V, Vejsova M, Vale-Silva LA. Comparison of disk diffusion test and Etest for voriconazole and fluconazole susceptibility testing. Folia Microbiol. 2008; 53: 153-60.
26. CLSI. National Committee for Clinical Laboratory Standards. Reference method for broth dilution antifungal susceptibility testing of filamentous fungi; Approved standard-second edition. Document M38-A2. 2008.
27. Qiao J, Liu W, Li R. Antifungal resistance mechanisms of Aspergillus. Jpn J Med Mycol. 2008; 49: 157-63.
28. Balajee SA, Imhof A, Gribskov JL, Marr KA. Determination of antifungal drug susceptibilities of Aspergillus species by a fluorescence-based microplate assay. J Antimicrob Chemother. 2005; 55: 102-5.
29. Lass-Florl C, Alastruey-Izquierdo A, Cuenca-Estrella M, Perkhofer S, Rodriguez-Tudela JL. In vitro activities of various antifungal drugs against Aspergillus terreus: Global assessment using the methodology of the European committee on antimicrobial susceptibility testing. Antimicrob Agents Chemother. 2009; 53: 794-5.
30. Lass-Florl C, Mayr A, Perkhofer S, et al. Activities of antifungal agents against yeasts and filamentous fungi: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing. Antimicrob Agents Chemother. 2008; 52: 3637-41.
31. Lass-Florl C, Perkhofer S. In vitro susceptibility-testing in Aspergillus species. Mycoses. 2008; 51: 437-46.
32. Denning DW, Venkateswarlu K, Oakley KL, et al. Itraconazole resistance in Aspergillus fumigatus. Antimicrob Agents Chemother. 1997; 41: 1364-8.
33. Denning DW, Radford SA, Oakley KL, Hall L, Johnson EM, Warnock DW. Correlation between in vitro susceptibility testing to itraconazole and in vivo outcome of Aspergillus fumigatus infection. J Antimicrob Chemother. 1997; 40: 401-14.
34. Rodriquez Tudela JL, Donnelly JP, Arendrup MC, et al. EUCAST technical note on the method for the determination of broth dilution minimum inhibitory concentrations of antifungal agents for conidia-forming moulds. Clin Microbiol Infect 2008; 14: 982-984.
35. Pfaller JB, Messer SA, Hollis RJ, Diekema DJ, Pfaller MA. In vitro susceptibility testing of Aspergillus spp.: comparison of Etest and reference microdilution methods for determining voriconazole and itraconazole MICs. J Clin Microbiol. 2003; 41: 1126-9.
36. Pfaller MA, Messer SA, Boyken L, Hollis RJ, Diekema DJ. In vitro susceptibility testing of filamentous fungi: comparison of Etest and reference M38-A microdilution methods for determining posaconazole MICs. Diagn Microbiol Infect Dis. 2003; 45: 241-4.
37. Meletiadis J, Mouton JW, Meis JF, Bouman BA, Verweij PE. Comparison of the Etest and the sensititre colorimetric methods with the NCCLS proposed standard for antifungal susceptibility testing of Aspergillus species. J Clin Microbiol. 2002; 40: 2876-85.
38. Verweij PE, Howard SJ, Melchers WJ, Denning DW. Azole-resistance in Aspergillus: proposed nomenclature and breakpoints. Drug Resist Updat. 2009; 12: 141-7.
39. Lass-Florl C. In vitro susceptibility testing in Aspergillus species: an update. Future Microbiol. 2010; 5: 789-99.
40. Balajee SA, Gribskov JL, Hanley E, Nickle D, Marr KA. Aspergillus lentulus sp. nov., a new sibling species of A. fumigatus. Eukaryot Cell. 2005; 4: 625-32.
41. Balajee SA, Nickle D, Varga J, Marr KA. Molecular studies reveal frequent misidentification of Aspergillus fumigatus by morphotyping. Eukaryot Cell. 2006; 5: 1705-12.
42. Yaguchi T, Horie Y, Tanaka R, Matsuzawa T, Ito J, Nishimura K. Molecular phylogenetics of multiple genes on Aspergillus section Fumigati isolated from clinical specimens in Japan. Jpn J Med Mycol. 2007; 48: 37-46.
43. Krishnan S, Manavathu EK, Chandrasekar PH. Aspergillus flavus: an emerging non-fumigatusAspergillus species of significance. Mycoses. 2009; 52: 206-22.
44. Hadrich I, Makni F, Sellami H, et al. Invasive aspergillosis: epidemiology and environmental study in haematology patients (Sfax, Tunisia). Mycoses. 2010; 53: 443-7.
45. Baddley JW, Marr KA, Andes DR, et al. Patterns of susceptibility of Aspergillus isolates recovered from patients enrolled in the Transplant-Associated Infection Surveillance Network. J Clin Microbiol. 2009; 47: 3271-5.
46. Balajee SA, Kano R, Baddley JW, et al. Molecular identification of Aspergillus species collected for the Transplant-Associated Infection Surveillance Network. J Clin Microbiol. 2009; 47: 3138-41.
47. Gomez-Lopez A, Garcia-Effron G, Mellado E, Monzon A, Rodriguez-Tudela JL, Cuenca-Estrella M. In vitro activities of three licensed antifungal agents against Spanish clinical isolates of Aspergillus spp. Antimicrob Agents Chemother. 2003; 47: 3085-8.
48. Lionakis MS, Lewis RE, Torres HA, Albert ND, Raad II, Kontoyiannis DP. Increased frequency of non-fumigatus Aspergillus species in amphotericin B- or triazole-pre-exposed cancer patients with positive cultures for aspergilli. Diagn Microb Infect Dis. 2005; 52: 15-20.
49. Hedayati MT, Pasqualotto AC, Warn PA, Bowyer P, Denning DW. Aspergillus flavus: human pathogen, allergen and mycotoxin producer. Microbiology. 2007; 153: 1677-92.
50. Koss T, Bagheri B, Zeana C, Romagnoli MF, Grossman ME. Amphotericin B-resistant Aspergillus flavus infection successfully treated with caspofungin, a novel antifungal agent. J Am Acad Dermatol. 2002; 46: 945-7.
51. Balajee SA, Lindsley MD, Iqbal N, Ito J, Pappas PG, Brandt ME. Nonsporulating clinical isolate identified as Petromyces alliaceus (anamorph Aspergillus alliaceus) by morphological and sequence-based methods. J Clin Microbiol. 2007; 45: 2701-3.
52. Blum G, Perkhofer S, Haas H, et al. Potential basis for amphotericin B resistance in Aspergillus terreus. Antimicrob Agents Chemother. 2008; 52: 1553-5.
53. Morace G, Drago M, Scaltrito MM, Conti S, Fanti F, Polonelli L. In vitro activity (MIC and MFC) of voriconazole, amphotericin B, and itraconazole against 192 filamentous fungi: the GISIA-2 study. J Chemother. 2007; 19: 508-13.
54. Walsh TJ, Petraitis V, Petraitiene R, et al. Experimental pulmonary aspergillosis due to Aspergillus terreus: pathogenesis and treatment of an emerging fungal pathogen resistant to amphotericin B. J Infect Dis. 2003; 188: 305-19.
55. Deak E, Wilson SD, White E, Carr JH, Balajee SA. Aspergillus terreus accessory conidia are unique in surface architecture, cell wall composition and germination kinetics. PLoS One. 2009; 4: e7673.
56. Auberger J, Lass-Florl C, Clausen J, et al. First case of breakthrough pulmonary Aspergillus niveus infection in a patient after allogeneic hematopoietic stem cell transplantation. Diagn Microbiol Infect Dis. 2008; 62: 336-9.
57. Balajee SA, Baddley JW, Peterson SW, et al. Aspergillus alabamensis, a new clinically relevant species in the section Terrei. Eukaryot Cell. 2009; 8: 713-22.
58. Person AK, Chudgar SM, Norton BL, Tong BC, Stout JE. Aspergillus niger: an unusual cause of invasive pulmonary aspergillosis. J Med Microbiol. 2010; 59: 834-8.
59. Kaya AD, Kiraz N. In vitro susceptibilities of Aspergillus spp. causing otomycosis to amphotericin B, voriconazole and itraconazole. Mycoses. 2007; 50: 447-50.
60. Howard SJ, Harrison E, Bowyer P, Varga J, Denning DW. Cryptic species and azole resistance in the Aspergillus niger complex. Antimicrob Agents Chemother. 2011; 55: 4802-9.
61. Segal BH, DeCarlo ES, Kwon-Chung KJ, Malech HL, Gallin JI, Holland SM. Aspergillus nidulans infection in chronic granulomatous disease. Medicine. 1998; 77: 345-54.
62. Kontoyiannis DP, Lewis RE, May GS, Osherov N, Rinaldi MG. Aspergillus nidulans is frequently resistant to amphotericin B. Mycoses. 2002; 45: 406-7.
63. Dannaoui E, Persat F, Monier MF, Borel E, Piens MA, Picot S. In vitro susceptibility of Aspergillus spp. isolates to amphotericin B and itraconazole. J Antimicrob Chemother. 1999; 44: 553-5.
64. Verweij PE, Varga J, Houbraken J, et al. Emericella quadrilineata as cause of invasive aspergillosis. Emerg Infect Dis. 2008; 14: 566-72.
65. Morgan J, Wannemuehler KA, Marr KA, et al. Incidence of invasive aspergillosis following hematopoietic stem cell and solid organ transplantation: interim results of a prospective multicenter surveillance program. Med Mycol. 2005; 43: S49-58.
66. Pavie J, Lacroix C, Hermoso DG, et al. Breakthrough disseminated Aspergillus ustus infection in allogeneic hematopoietic stem cell transplant recipients receiving voriconazole or caspofungin prophylaxis. J Clin Microbiol. 2005; 43: 4902-4.
67. Houbraken J, Due M, Varga J, Meijer M, Frisvad JC, Samson RA. Polyphasic taxonomy of Aspergillus section Usti. Stud Mycol. 2007; 59: 107-28.
68. Varga J, Houbraken J, van Der Lee HA, Verweij PE, Samson RA. Aspergillus calidoustus sp. nov., causative agent of human infections previously assigned to Aspergillus ustus. Eukaryot Cell. 2008; 7: 630-8.
69. Verweij PE, van den Bergh MF, Rath PM, de Pauw BE, Voss A, Meis JF. Invasive aspergillosis caused by Aspergillus ustus: case report and review. J Clin Microbiol. 1999; 37: 1606-9.
70. Alanio A, Sitterle E, Liance M, et al. Low prevalence of resistance to azoles in Aspergillus fumigatus in a French cohort of patients treated for haematological malignancies. J Antimicrob Chemother. 2011; 66: 371-4.
71. Araujo R, Pina-Vaz C, Rodrigues AG. Susceptibility of environmental versus clinical strains of pathogenic Aspergillus. Int J Antimicrob Agents. 2007; 29: 108-11.
72. Snelders E, van der Lee HA, Kuijpers J, et al. Emergence of azole resistance in Aspergillus fumigatus and spread of a single resistance mechanism. PLoS Med. 2008; 5: e219.
73. Guinea J, Recio S, Pelaez T, Torres-Narbona M, Bouza E. Clinical isolates of Aspergillus species remain fully susceptible to voriconazole in the post-voriconazole era. Antimicrob Agents Chemother. 2008; 52: 3444-6.
74. Diaz-Guerra TM, Mellado E, Cuenca-Estrella M, Rodriguez-Tudela JL. A point mutation in the 14alpha-sterol demethylase gene cyp51A contributes to itraconazole resistance in Aspergillus fumigatus. Antimicrob Agents Chemother. 2003; 47: 1120-4.
75. Mellado E, Garcia-Effron G, Alcazar-Fuoli L, et al. A new Aspergillus fumigatus resistance mechanism conferring in vitro cross-resistance to azole antifungals involves a combination of cyp51A alterations. Antimicrob Agents Chemother. 2007; 51: 1897-904.
76. da Silva Ferreira ME, Capellaro JL, dos Reis Marques E, et al. In vitro evolution of itraconazole resistance in Aspergillus fumigatus involves multiple mechanisms of resistance. Antimicrob Agents Chemother. 2004; 48: 4405-13.
77. Escribano P, Recio S, Pelaez T, Bouza E, Guinea J. Aspergillus fumigatus strains with mutations in the cyp51A gene do not always show phenotypic resistance to itraconazole, voriconazole, or posaconazole. Antimicrob Agents Chemother. 2011; 55: 2460-2.
78. Bellete B, Raberin H, Morel J, Flori P, Hafid J, Manhsung RT. Acquired resistance to voriconazole and itraconazole in a patient with pulmonary aspergilloma. Med Mycol. 2010; 48: 197-200.
79. Thors VS, Bierings MB, Melchers WJ, Verweij PE, Wolfs TF. Pulmonary aspergillosis caused by a pan-azole-resistant Aspergillus fumigatus in a 10-year-old boy. Pediatr Infect Dis J. 2011; 30: 268-70.
80. Pfaller M, Boyken L, Hollis R, et al. Use of epidemiological cutoff values to examine 9-year trends in susceptibility of Aspergillus species to the triazoles. J Clin Microbiol. 2011; 49: 586-90.
81. Verweij PE, Mellado E, Melchers WJ. Multiple-triazole-resistant aspergillosis. New Engl J Med. 2007; 356: 1481-3.
82. Gollapudy R, Ajmani S, Kulkarni SA. Modeling and interactions of Aspergillusfumigatus lanosterol 14-alpha demethylase 'A' with azole antifungals. Bioorgan Med Chem. 2004; 12: 2937-50.
83. Snelders E, Karawajczyk A, Verhoeven RJ, et al. The structure-function relationship of the Aspergillus fumigatus cyp51A L98H conversion by site-directed mutagenesis: the mechanism of L98H azole resistance. Fungal Genet Biol. 2011; 48: 1062-70.
84. Xiao L, Madison V, Chau AS, Loebenberg D, Palermo RE, McNicholas PM. Three-dimensional models of wild-type and mutated forms of cytochrome P450 14alpha-sterol demethylases from Aspergillus fumigatus and Candida albicans provide insights into posaconazole binding. Antimicrob Agents Chemother. 2004; 48: 568-74.
85. Lockhart SR, Frade JP, Etienne KA, Pfaller MA, Diekema DJ, Balajee SA. Azole resistance in Aspergillus fumigatus isolates from the ARTEMIS global surveillance is primarily due to the TR/L98H mutation in the cyp51A gene. Antimicrob Agents Chemother. 2011; 55: 4465-8.
86. Verweij PE, Camps SM, Kema GH, Melchers WJ. Comment on: Low prevalence of resistance to azoles in Aspergillus fumigatus in a French cohort of patients treated for haematological malignancies. J Antimicrob Chemother. 2011; 66: 954-5.
87. Masia Canuto M, Gutierrez Rodero F. Antifungal drug resistance to azoles and polyenes. Lancet Infect Dis. 2002; 2: 550-63.
88. Miyazaki Y, Geber A, Miyazaki H, et al. Cloning, sequencing, expression and allelic sequence diversity of ERG3 (C-5 sterol desaturase gene) in Candida albicans. Gene. 1999; 236: 43-51.
89. Kelly SL, Lamb DC, Kelly DE, et al. Resistance to fluconazole and cross-resistance to amphotericin B in Candida albicans from AIDS patients caused by defective sterol delta5, 6-desaturation. FEBS Lett. 1997; 400: 80-2.
90. Walsh TJ, Anaissie EJ, Denning DW, et al. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis. 2008; 46: 327-60.
91. Arendrup MC, Perkhofer S, Howard SJ, et al. Establishing in vitro-in vivo correlations for Aspergillus fumigatus: the challenge of azoles versus echinocandins. Antimicrob Agents Chemother. 2008; 52: 3504-11.
92. Madureira A, Bergeron A, Lacroix C, et al. Breakthrough invasive aspergillosis in allogeneic haematopoietic stem cell transplant recipients treated with caspofungin. Int J Antimicrob Agents. 2007; 30: 551-4.
93. Gardiner RE, Souteropoulos P, Park S, Perlin DS. Characterization of Aspergillusfumigatus mutants with reduced susceptibility to caspofungin. Med Mycol. 2005; 43: S299-305.
94. Eschertzhuber S, Velik-Salchner C, Hoermann C, Hoefer D, Lass-Florl C. Caspofungin-resistant Aspergillus flavus after heart transplantation and mechanical circulatory support: a case report. Transpl Infect Dis. 2008; 10: 190-2.
95. Liu W, May GS, Lionakis MS, Lewis RE, Kontoyiannis DP. Extra copies of the Aspergillusfumigatus squalene epoxidase gene confer resistance to terbinafine: genetic approach to studying gene dose-dependent resistance to antifungals in A. fumigatus. Antimicrob Agents Chemother. 2004; 48: 2490-6.